Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to determine the relative bioavailability, safety and tolerability of SPARC001 and Reference001 in healthy, adult, male and female subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SPARC001 type I | Experimental | Treatment type I |
|
| SPARC001 type II | Experimental | Treatment type II |
|
| Reference001 type I | Active Comparator | Treatment type I |
|
| Reference type II | Active Comparator | Treatment type II |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SPARC001 type I | Drug | Treatment type I |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUC | 48 hours | |
| Cmax | 48 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse event | 25 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SPARC Site 01 | Secaucus | New Jersey | 07094 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| SPARC001 type II | Drug | Treatment type II |
|
| Reference001 type I | Drug | Hydrocodone-Acetaminophen |
|
| Reference001 type II | Drug | Hydrocodone-Acetaminophen |
|